Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy

Shindoh, Junichi; Kaseb, Ahmed O.; Vauthey, Jean‐Nicolas

doi:10.1159/000346222

Cited by 24 publications

(19 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because most patients are diagnosed with advanced disease, only 30% of patients receive potentially curative therapies, such as surgical resection [4,5], transplantation [6,7] or percutaneous ablation [8,9,10]. The majority of patients with unresectable HCC usually undergo palliative treatment, such as transarterial chemoembolization (TACE) [11], hepatic arterial infusion chemotherapy [12] and systemic chemotherapy, including molecular-targeting agents [12,13,14,15,16,17].…”

Section: Introductionmentioning

confidence: 99%

Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Arizumi

Ueshima

Chishina

et al. 2014

Dig Dis

View full text Add to dashboard Cite

Background: Sorafenib is a molecular-targeting agent showing improved overall survival (OS) for advanced hepatocellular carcinoma (HCC). Although tumor dormancy, characterized by stable tumor status or stable disease (SD) without tumor regression, is a unique feature of sorafenib treatment, the contribution of SD to OS remains debatable. This study aimed to clarify the correlation between SD periods and OS in patients with HCC treated with sorafenib. Methods: From May 2009 to January 2013, 269 patients with advanced-stage HCC were treated with sorafenib at the Kinki University Hospital. The antitumor response of sorafenib was evaluated in 158 patients using the modified Response Evaluation Criteria in Solid Tumors, and patients with SD were divided into two subgroups according to the median duration of SD: short SD (<3 months) and long SD (≥3 months). The relationship between the duration of SD and OS was analyzed among patients with complete (CR) and partial response (PR), and long and short SD using the Kaplan-Meier method. Results: The median OS was 5.7 months in the short SD, 20.8 months in the long SD and 17.9 months in the CR + PR group. Although the duration of OS was significantly longer in the long SD group than the short SD group, no difference in OS was detected between the patients with CR + PR and patients with long SD. The impact of long SD on OS could be as strong as that of CR + PR. Conclusion: Achievement of long SD is one of the important goals for improving survival in patients with HCC treated with sorafenib.

show abstract

Section: Introductionmentioning

confidence: 99%

Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Arizumi

Ueshima

Chishina

et al. 2014

Dig Dis

View full text Add to dashboard Cite

show abstract

“…The rationale of adjuvant systemic chemotherapy is to eliminate circulating tumor cells or microscopic tumor foci [66]. Although a small-scale RCT showed a potential benefit of 1-hexylcarbamoyl-5-fluorouracil on recurrence-free survival in stage I HCC, results in stage II HCC patients are missing [67].…”

Section: Current Options For the Prevention Of Recurrence After Curatmentioning

confidence: 99%

Adjuvant Therapy for Hepatocellular Carcinoma after Curative Treatment

Jeng

Lin

Chen

et al. 2014

Dig Dis

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common malignancy in the world. Although resection and various locoregional therapies can achieve eradication or complete ablation of small HCC, HCC recurrence after these therapies is still common. Although candidates for medical ablation usually exhibit compensated hepatic functional status, the frequent recurrence of HCC after successful ablation contributes to short survival. Therefore, attempts to prevent HCC recurrence are essential to prolong survival. Efforts in preventing HCC recurrence after curative therapies include prevention of early recurrence by improving liver immunity and eliminating microscopic tumor foci or micrometastases, and prevention of late recurrence by reducing the hepatitis activity and using antiviral therapies based on viral suppression/eradication. In HCC with vascular invasion, adjuvant transcatheter arterial chemoembolization should be considered to provide better control. Whether the adjuvant use of sorafenib may suppress microscopic tumor foci or micrometastases may be unveiled in the near future. This review article will update the algorithms, novel medication or study drugs in the prevention of HCC after curative therapies.

show abstract

“…Subclasses in the classification of HCC were also discussed. Session V, ‘Controversial Issues in Surgical Treatment', focused on controversial points during surgical techniques [13,14,15,16]. …”

Section: Tablementioning

confidence: 99%

Emerging Strategies for the Management of Hepatocellular Carcinoma

Kudo

2014

Dig Dis

View full text Add to dashboard Cite

Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy

Cited by 24 publications

References 61 publications

Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Adjuvant Therapy for Hepatocellular Carcinoma after Curative Treatment

Emerging Strategies for the Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About